跳至主要内容
临床试验/NCT01528540
NCT01528540已完成不适用

Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a RCT

Asian Institute of Gastroenterology, India1 个研究点 分布在 1 个国家目标入组 87 人开始时间: 2012年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
87
试验地点
1
主要终点
Change in the pain score

研究概览

简要总结

Study hypothesis: Combination of antioxidants and pregabalin results in better pain relief than placebo in patients with chronic pancreatitis.

Chronic pancreatitis (CP) is a clinical enigma, with pain being the most distressing symptom that brings the patient to clinical attention. Pain in chronic pancreatitis is multifactorial, and may be related to pancreatic ductal hypertension, tissue hypertension, inflammatory cytokines, oxidative stress and neuropathic mechanisms like mechanical allodynia, inflammatory hyperalgesia and temporal summation. The mainstay of treatment for pain in CP due to pancreatic ductal stone is endotherapy (ESWL and ERCP). Recent randomized controlled trials have shown that antioxidant cocktail and pregabalin (a presynaptic voltage gated calcium channel blocking agent) can result in significant reduction of pain in CP.

In this study, the investigators will study the efficacy of the combination of antioxidants and pregabalin in reducing pain and compare that with placebo. The investigators will randomize patients with documented chronic pancreatitis with recurrent/persistent pain after undergoing endotherapy and ductal clearance into three groups: Group A- antioxidants + pregabalin; Group B- Placebo. The primary outcome will be change in pain score and the secondary outcomes will be change in the number of painful days, analgesic requirements, quality of life and depression scale. Pain score will be quantified by the Izbicki pain score and visual analog scale; while quality of life and depression will be measured by the EORTC QLQ-C30/PAN26 and Beck depression inventory respectively. Comparison between Group A vs B will be made by the Chi square test/Fischer Exact and the Student's 't' tests respectively and analysis will be done on a intention to treat and per protocol basis. With an expected improvement of pain by 40% (at 80% power and alpha of 0.05) and adjusting for a presumed 10% drop out rate, the required sample size in each group will be at least 40.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Epigastric pain +/- radiation at least thrice in one month over the past three month.
  • Endotherapy/Surgery and ducal clearance

排除标准

  • Age <18 and >65yrs
  • MPD and biliary obstruction
  • Pancreatic neoplastic lesions
  • Acute flare
  • Pancreatic pseudocysts
  • Cardiac and renal diseases
  • Use of other anti epileptics
  • Hypersensitivity to gabapentin/pregabalin

研究组 & 干预措施

Placebo

Placebo Comparator

This group will contain a placebo for antioxidant cocktail and pregabalin

干预措施: Placebo (Drug)

Antioxidant plus pregabalin

Experimental

This group will contain antioxidant cocktail and pregabalin

干预措施: Antioxidant plus Pregabalin (Drug)

结局指标

主要结局

Change in the pain score

时间窗: Baseline and 8weeks

Pain score will be assessed by the Izbicki pain score, Visual analog scale and painDETECT tool for neuropathic pain.

次要结局

  • Change in number of painful days(Baseline and 8weeks)
  • Change in analgesic requirement(Baseline and 8weeks)
  • Change in quality of life(Baseline and 8weeks)
  • Change in depression scale(Baseline and 8weeks)

研究者

发起方
Asian Institute of Gastroenterology, India
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验